Astatine-211 based radionuclide therapy: Current clinical trial landscape
P Albertsson, T Bäck, K Bergmark, A Hallqvist… - Frontiers in …, 2023 - frontiersin.org
Astatine-211 (211At) has physical properties that make it one of the top candidates for use
as a radiation source for alpha particle-based radionuclide therapy, also referred to as …
as a radiation source for alpha particle-based radionuclide therapy, also referred to as …
Radiochemistry: a hot field with opportunities for cool chemistry
Recent Food and Drug Administration (FDA) approval of diagnostic and therapeutic
radiopharmaceuticals and concurrent miniaturization of particle accelerators leading to …
radiopharmaceuticals and concurrent miniaturization of particle accelerators leading to …
Preclinical studies of a PARP targeted, Meitner-Auger emitting, theranostic radiopharmaceutical for metastatic ovarian cancer
SLV Hoffman, JC Mixdorf, O Kwon, TR Johnson… - Nuclear Medicine and …, 2023 - Elsevier
Advanced ovarian cancer currently has few therapeutic options. Poly (ADP-ribose)
polymerase (PARP) inhibitors bind to nuclear PARP and trap the protein-inhibitor complex to …
polymerase (PARP) inhibitors bind to nuclear PARP and trap the protein-inhibitor complex to …
神经母细胞瘤动物模型研究进展与应用
谭志刚， 刘锦信， 郑楚雅， 廖文峰， 冯露平， 彭红丽… - 实验动物与比较 …, 2023 - slarc.org.cn
神经母细胞瘤(neuroblastoma, NB) 是儿童最常见的实体恶性肿瘤, 居我国儿童肿瘤发病率第四
位, 占儿童肿瘤死亡人数的15%, 高危患者存活率低. 目前对于NB 的发病及药物治疗机制知之甚 …
位, 占儿童肿瘤死亡人数的15%, 高危患者存活率低. 目前对于NB 的发病及药物治疗机制知之甚 …
Can current preclinical strategies for radiopharmaceutical development meet the needs of targeted alpha therapy?
Preclinical studies are essential for effectively evaluating TAT radiopharmaceuticals. Given
the current suboptimal supply chain of these radionuclides, animal studies must be refined …
the current suboptimal supply chain of these radionuclides, animal studies must be refined …
Amino Acid Metabolism Subtypes in Neuroblastoma Identifying Distinct Prognosis and Therapeutic Vulnerabilities
X Zhou, Z Zhou, X Qin, J Cheng, Y Fu… - Journal of Proteome …, 2024 - ACS Publications
Although amino acid (AA) metabolism is linked to tumor progression and could serve as an
attractive intervention target, its association with neuroblastoma (NB) is unknown. Based on …
attractive intervention target, its association with neuroblastoma (NB) is unknown. Based on …
Other novel PET radiotracers for breast cancer
Many novel PET radiotracers have demonstrated potential use in breast cancer. Although
not currently approved for clinical use in the breast cancer population, these innovative …
not currently approved for clinical use in the breast cancer population, these innovative …
The Different Strategies for the Radiolabeling of [211At]-Astatinated Radiopharmaceuticals
J Gao, M Li, J Yin, M Liu, H Wang, J Du, J Li - Pharmaceutics, 2024 - mdpi.com
Astatine-211 (211At) has emerged as a promising radionuclide for targeted alpha therapy of
cancer by virtue of its favorable nuclear properties. However, the limited in vivo stability of …
cancer by virtue of its favorable nuclear properties. However, the limited in vivo stability of …
Alpha Atlas: Mapping global production of α-emitting radionuclides for targeted alpha therapy
M Tosato, C Favaretto, J Kleynhans… - Nuclear Medicine and …, 2024 - Elsevier
Abstract Targeted Alpha Therapy has shown great promise in cancer treatment, sparking
significant interest over recent decades. However, its broad adoption has been impeded by …
significant interest over recent decades. However, its broad adoption has been impeded by …
PARP inhibitor resistance mechanisms and PARP inhibitor derived imaging probes
T Yu, BH Lok - Expert Review of Anticancer Therapy, 2024 - Taylor & Francis
Introduction Poly (ADP-ribose) polymerase 1 (PARP1) inhibition has become a major target
in anticancer therapy. While PARP inhibitors (PARPi) are approved for homologous …
in anticancer therapy. While PARP inhibitors (PARPi) are approved for homologous …